Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peri

[
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peri
[og_img]
https://www.investing.com/news/press-releases/intellia-announces-positive-twoyear-followup-data-from-ongoing-phase-1-study-of-nexiguran-ziclumeran-nexz-in-patients-with-hereditary-transthyretin-attr-amyloidosis-with-polyneuropathy-at-peri-93CH-4051644


Investing.com